Association Between Timp-3/Angiotensin II, Profile and Cardiac Remodeling in Patients with Essential Hypertension and Heart Failure with Mid-Range Ejection Fraction| Biomed Grid

Background and Aims: Arterial hypertension (AH) is a leading cause for heart failure with mid-range ejection fraction (HfmrEF). The aim of our study was to: 1. Measure levels of tissue inhibitor of matrix metalloprotease-3 (TIMP-3) and Angiotensin II (AII) in sera of patients with AH and HFmrEF. 2. In sera of controls. Material and Methods: 56 patients with AH and HfmrEF were examined, mean age 65.62±9.69; and 22 age and sex matched healthy subjects, mean age 56.4±5.53. 41 of patients were with hypertension mediated organ damage and 15 were without. Patients were divided in two subgroupssubjects with left ventricular hypertrophy (n=32); (HFmrEF+LVH) and subjects without left ventricular hypertrophy (n=24); (HFmrEF-LVH). ELISA was used for measuring AII and TIMP-3. Results: Patients with HFmrEF-LVH showed higher levels of TIMP-3: 7.747 (1.21916.725) than HFmrEF+LVH 4.693 (2.06210.463); (KW=0.48; p=0.48) and healthy controls 6.460 (1.00712.520); (p>0.05), but not significantly. TIMP3 showed correlation with grade of AH (r=0.85; p=0.02) and stage of AH (r=-0.52; p=0.05); and PLVW (r=-0.40; p=0.03). Patients with HFmrEF+LVH showed statistically significantly higher levels of AII: 8.533 (1.47713.009) than HFmrEF-LVH 1.333 (0.4776.932) and healthy controls 1.539 (0.2745.218); (KW=3.48; p=0.04). AII correlated with TIMP-3 (r=-0.50; p=0.0001), hypertensive cerebrovascular damage (r=0.57; p=0.0009), DBP (r=0.30; p=0.05), stage with AH (r=0.47; p=0.001); CK-MB (r=0.42; p=0.002) and UA (r=0.35; p=0.02). Conclusion: Our data suggest an association between changes in levels of TIMP-3/Angiotensin II profile and cardiac remodeling. Determination of serum TIMP-3/Angiotensin II profile may be a useful method for monitoring of development and progression of LVH